aavrh.10cuhcln2
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01161576)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tripeptidyl-peptidase 1Supplementation
supplementation - CLN2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aavrh.10cuhcln2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01161576 | Phase 1 | Aug 1, 2010 | Cornell University, National Institutes of Health (NIH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1